Abbonarsi

The impact of osteoporosis and vertebral compression fractures on mortality and association with pulmonary function in COPD: A meta-analysis - 02/01/22

Doi : 10.1016/j.jbspin.2021.105249 
Loukas Kakoullis a, , Fotios Sampsonas a, Vasileios Karamouzos b, George Kyriakou c, Konstantinos Parperis d, Eleni Papachristodoulou c, Costas Christophi e, f, Dimosthenis Lykouras a, Christina Kalogeropoulou g, Dimitrios Daoussis h, George Panos i, Dimitrios Velissaris j, Kyriakos Karkoulias a, Kostas Spiropoulos a
a Department of Respiratory Medicine, University General Hospital of Patras, Patras, Greece 
b Intensive Care Unit, University General Hospital of Patras, Patras, Greece 
c Department of Medicine, University of Patras School of Health Sciences, Patras, Greece 
d Department of Internal Medicine, Division of Rheumatology, University of Cyprus Medical School, Nicosia, Cyprus 
e Cyprus International Institute for Environmental and Public Health, Cyprus University of Technology, Limassol, Cyprus 
f Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA 
g Department of Radiology, University General Hospital of Patras, Patras, Greece 
h Department of Rheumatology, University of Patras Medical School, Patras, Greece 
i Department of Internal Medicine, Division of Infectious Diseases, University General Hospital of Patras, Patras, Greece 
j Department of Internal Medicine, University General Hospital of Patras, Patras, Greece 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

pagine 9
Iconografia 4
Video 0
Altro 0

Highlights

Osteoporosis is a well-known comorbidity of COPD, with an estimated prevalence of 38%.
This is the first meta-analysis to evaluate the impact of osteoporosis in COPD.
The presence of osteoporosis is associated with increased mortality in COPD patients.
Osteoporosis is also associated with decreased FEV1 and FEV1/FVC in COPD patients.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Objective

Osteoporosis is highly prevalent among patients with chronic obstructive pulmonary disease (COPD) and most commonly presents as a vertebral compression fracture (VCF). Our objective was to quantify the effect of osteoporosis and VCFs on the mortality and pulmonary function tests (PFTs), such as forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), of patients with COPD.

Methods

A PubMed/Medline search was conducted using the search terms “chronic obstructive pulmonary disease”, “osteoporosis” and “vertebral compression fracture”. Meta-analyses were conducted to evaluate the differences in mortality and PFTs between patients with COPD with and without osteoporosis or VCFs, according to PRISMA guidelines. PROSPERO registration: CRD42019120335.

Results

Of the 896 abstracts identified, 27 studies describing 7662 patients with COPD of which 1883 (24.6%) had osteoporosis or VCFs, were included. Random effects model analysis demonstrated that patients with COPD and osteoporosis or VCFs had an increased OR for mortality of 2.40 (95% CI: 1.24; 4.64, I2=89%, P<0.01), decreased FEV1/FVC with a mean difference of −4.80% (95% CI: −6.69; −2.90, I2=83%, P<0.01) and decreased FEV1, with a mean difference of −4.91% (95% CI: −6.51; −3.31, I2=95%, P<0.01) and −0.41 L (95% CI: −0.59; −0.24, I2=97%, P<0.01), compared to control subjects. Apart from FEV1 (liters) in subgroup 1 (P=0.06), all subgroup analyses found significant differences between groups, as did sensitivity analysis of low risk of bias studies.

Conclusion

Osteoporosis and VCFs are associated with a significant reduction in survival and pulmonary function among patients with COPD.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Chronic obstructive pulmonary disease, Survival, Osteoporosis


Mappa


© 2021  Société française de rhumatologie. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 89 - N° 1

Articolo 105249- Gennaio 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Tight control and treat-to-target in axial spondyloarthritis. Where are we?
  • Daniel Wendling, Pascal Claudepierre, Philippe Goupille, Thao Pham, Clément Prati
| Articolo seguente Articolo seguente
  • How to taper glucocorticoids in inflammatory rheumatic diseases? A narrative review of novel evidence in rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis
  • Frank Buttgereit, Andriko Palmowski

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.